1. Donald PR, Diacon AH, Lange C, Demers AM, von Groote-Biddlingmeier F, Nardell E. Int J Tuberc Lung Dis. 2018 Sep 1;22(9):972-982. doi: 10.5588/ijtld.18.0173.
  2. Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr. Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770-18. doi: 10.1128/AAC.00770-18. [Epub ahead of print]
  3. Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH. BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6.
  4. Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, Nachman S, Smith B, Diacon AH, Hesseling AC, Garcia-Prats AJ. Br J Clin Pharmacol. 2018 Jun 27. doi: 10.1111/bcp.13696. [Epub ahead of print]
  5. Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R. Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy02
  6. Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T. J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print
  7. Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, Boeree MJ, Simonsson USH. J Infect Dis. 2018 Aug 14;218(6):991-999. doi: 10.1093/infdis/jiy242.
  8. Shaw JA, Irusen EM, Diacon AH, Koegelenberg CF. Clin Respir J. 2018 May;12(5):1779-1786. doi: 10.1111/crj.12900.
  9. Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH. BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7
  10. Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.
  11. Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1 Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02229-17. doi: 10.1128/AAC.02229-17. Print 2018 Jan. No abstract available
  12. Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr. Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.
  13. Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA. Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct
  14. Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson US. A population pharmacokinetic model incorporating saturable pharmacokinetics and auto-induction for high rifampicin doses. Clin Pharmacol Ther. 2017.
  15. Kistan J, Laher F, Otwombe K, Panchia R, Mawaka N, Lebina L, Diacon A, Kana B, Martinson N. Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa. Trans R Soc Trop Med Hyg. 2017;111:132-6.
  16. Kayigire XA, Friedrich SO, van der Merwe L, Diacon AH. Acquisition of Rifampin Resistance in Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2017;61.
  17. Heyckendorf J, Labugger I, van der Merwe L, Garcia-Basteiro AL, Diacon AH, Lange C. Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs. Tuberculosis (Edinb). 2017;102:31-3.
  18. Furin J, Diacon AH, Andries K. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline. Int J Tuberc Lung Dis. 2017;21:4-5.
  19. Diacon AH, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, Jenkins E, Dannemann B. Triplicate Sputum Cultures for Efficacy Evaluation of Novel Anti-tuberculosis Regimens. Am J Respir Crit Care Med. 2017.
  20. De Jager V, van der Merwe L, Venter A, Donald PR, Diacon AH. Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies. Antimicrob Agents Chemother. 2017;61.
  21. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PP, Hoelscher M, Pan Ac. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet Infectious diseases. 2017;17:39-49.
  22. Siwendu S, Mitchell M, Diacon AH, von Groote-Bidlingmaier F. Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis. Eur Respir J. 2016;47:670-2.
  23. Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, Group TCS. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47:564-74.
  24. Phillips PP, Mendel CM, Burger DA, Crook A, Nunn AJ, Dawson R, Diacon AH, Gillespie SH. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med. 2016;14:19.
  25. Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med. 2016;14:51.
  26. Kayigire XA, Friedrich SO, Karinja MN, van der Merwe L, Martinson NA, Diacon AH. Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells. Tuberculosis (Edinb). 2016;101:79-84.
  27. Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Peloquin CA, Alsultan A, Thiel B, Debanne SM, Boom WH, Diacon AH, Johnson JL. Early Bactericidal Activity of AZD5847 in Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2016.
  28. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang’wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016;20:290-4.
  29. Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, Garcia-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. beta-Lactams against Tuberculosis–New Trick for an Old Dog? N Engl J Med. 2016;375:393-4.
  30. Diacon AH, Van Baelen B, Theeuwes M. More on Treatment Outcomes in Multidrug-Resistant Tuberculosis. N Engl J Med. 2016;375:2609-10.
  31. Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheli L, Sasamalo M, Almeida D, Dorasamy A, Jentsch U, Gibson M, Everitt D, Eisenach KD, Diacon AH. Direct susceptibility testing of Mycobacterium tuberculosis for pyrazinamide using the BACTEC MGIT 960 system. J Clin Microbiol. 2016.
  32. Koegelenberg CF, Irusen EM, von Groote-Bidlingmaier F, Bruwer JW, Batubara EM, Diacon AH. The utility of ultrasound-guided thoracentesis and pleural biopsy in undiagnosed pleural exudates. Thorax. 2015;70:995-7.
  33. Kayigire XA, Friedrich SO, van der Merwe L, Donald PR, Diacon AH. Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments. Tuberculosis (Edinb). 2015;95:770-9.
  34. De Wet DR, Wright CA, Schubert PT, Koegelenberg CF, Louw M, Diacon AH. Mediastinal granulomatous lymphadenitis in a population at risk for HIV and tuberculosis. Diagn Cytopathol. 2015.
  35. Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH. The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. J Antimicrob Chemother. 2015;70:448-55.
  36. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. A Step toward an Optimized Rifampin Dose Completed. Am J Respir Crit Care Med. 2015;192:525-6.
  37. Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CF. Tuberculous pleural effusions: advances and controversies. J Thorac Dis 2015; 7: 981-991.
  38. Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2015; 59: 4129-4138..
  39. Rullas J, Dhar N, McKinney JD, Garcia-Perez A, Lelievre J, Diacon AH, Hugonnet JE, Arthur M, Angulo-Barturen I, Barros-Aguirre D, Ballell L. Combinations of beta-lactam antibiotics currently in clinical trials are efficacious in a DHP-I deficient mice model of TB infection. Antimicrob Agents Chemother 2015.
  40. Karinja MN, Esterhuizen TM, Friedrich SO, Diacon AH. Sputum Volume Predicts Sputum Mycobacterial Load during the First 2 Weeks of Antituberculosis Treatment. J Clin Microbiol 2015; 53: 1087-1091.
  41. Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH, on behalf of the Pan African Consortium for the Evaluation of Antituberculosis A. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015.
  42. Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis 2015.
  43. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-953.
  44. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015.
  45. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE, Pan AC. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191: 1058-1065.
  46. Solomons RS, Visser DH, Friedrich SO, Diacon AH, Hoek KG, Marais BJ, Schoeman JF, van Furth AM. Improved diagnosis of childhood tuberculous meningitis using more than one nucleic acid amplification test. Int J Tuberc Lung Dis 2015; 19: 74-80.
  47. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PloS one 2014; 9: e94462.
  48. Streicher EM, Maharaj K, York T, Van Heerden C, Barnard M, Diacon A, Mendel CM, Bosman ME, Hepple JA, Pym AS, Warren RM, van Helden PD. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. J Clin Microbiol 2014; 52: 4056-4057.
  49. Kibleur Y, Brochart H, Schaaf HS, Diacon AH, Donald PR. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis. Clinical drug investigation 2014; 34: 269-276.
  50. Karinja MN, Esterhuizen TM, Friedrich SO, Diacon AH. Sputum volume predicts sputum mycobacterial load during the first two weeks of anti-tuberculosis treatment. J Clin Microbiol 2014.
  51. Diacon AH, van der Merwe L, Demers AM, Von Groote-Bidlingmaier F, Venter A, Donald PR. Pre-treatment mycobacterial sputum load influences individual on-treatment measurements. Tuberculosis (Edinb) 2014; 94: 690-694.
  52. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, Group TCS. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
  53. Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert review of anti-infective therapy 2014; 12: 223-237.
  54. De Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 2014; 58: 6242-6250.
  55. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013;1:462-70
  56. Diacon AH, van der Merwe L, Demers AM, von Groote-Bidlingmaier F, Venter A, Donald PR. Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens. Tuberculosis (Edinb). 2014;94:148-51.
  57. Kolwijck E, Friedrich SO, Karinja MN, van Ingen J, Warren RM, Diacon AH. Early stationary phase culture supernatant accelerates growth of sputum cultures collected after inititation of anti-tuberculosis treatment. J Clin Microbiol 2013;51:1094-1098
  58. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis. Antimicrob Agents Chemother 2013;57:2199-2203
  59. Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 2013;8:579-585
  60. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, Heinrich N, Hoelscher M, Diacon AH. Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity. J Clin Microbiol. 2013;51:1894-8.
  61. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother. 2013;57:2199-203.
  62. Kolwijck E, Mitchell M, Venter A, Friedrich SO, Dawson R, Diacon AH. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies. J Clin Microbiol. 2013;51:1094-8.
  63. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012. 380:986-993.
  64. Diacon AH, von Groote-Bidlingmaier F, Donald PR. From magic mountain to table mountain. Swiss Med Wkly. 2012 Aug 22
  65. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. A phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012 Mar 19.
  66. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, Mc Neeley DF. Randomized pilot trial of 8 weeks of bedaquiline (TMC207) for MDR-TB: long-term outcome, tolerability and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012 Mar 5.
  67. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J Clin Microbiol. 2011 Dec;49(12):4341-2. Epub 2011 Oct 12.
  68. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect. 2011 Jun 30.
  69. Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb). 2012 Jan;92(1):1-8.
  70. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54.
  71. Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol. 2011 Aug;49(8):2827-31.
  72. Donald PR, Maritz JS, Diacon AH. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. Tuberculosis (Edinb). 2011 May;91(3):196-207.
  73. Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1561-5. Epub 2010 Sep 4.
  74. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients. Antimicrob Agents Chemother. 2010 May 24

 

 Further information can be found here: